Инфекция гриппа

Список литературы

Основные статьи

Centers for Disease Control and Prevention. Influenza (flu). Oct 2021 [internet publication].Полный текст

Статьи, указанные как источники

1. Brankston G, Gitterman L, Hirji Z, et al. Transmission of influenza A in human beings. Lancet Infect Dis. 2007 Apr;7(4):257-65. Аннотация

2. Uyeki TM, Bernstein HH, Bradley JS, et al. Clinical practice guidelines by the Infectious Diseases Society of America: 2018 update on diagnosis, treatment, chemoprophylaxis, and institutional outbreak management of seasonal influenza. Clin Infect Dis. 2019 Mar 5;68(6):e1-47.Полный текст  Аннотация

3. Neuzil KM, Wright PF, Mitchel EF Jr, et al. The burden of influenza illness in children with asthma and other chronic medical conditions. J Pediatr. 2000 Dec;137(6):856-64. Аннотация

4. Martin CM, Kunin CM, Gottlieb LS, et al. Asian influenza A in Boston, 1957-1958. Arch Intern Med. 1959 Apr;103(4):515-31. Аннотация

5. Nicholson K, Wood JM, Zambon M, et al. Influenza. Lancet. 2003 Nov 22;362(9397):1733-45. Аннотация

6. Zimmer SM, Burke DS. Historical perspective - Emergence of influenza A (H1N1) viruses. N Engl J Med. 2009 Jul 16;361(3):279-85. Аннотация

7. Australian Government Department of Health. Australian Influenza Surveillance Report. No. 12, 2017. Oct 2017 [internet publication].Полный текст

8. Public Health England. National flu immunisation programme plan. Jul 2021 [internet publication].Полный текст

9. Uyeki TM, Wentworth DE, Jernigan DB. Influenza activity in the US during the 2020-2021 season. JAMA. 2021 Jun 8;325(22):2247-8.Полный текст  Аннотация

10. Centers for Disease Control and Prevention. Reconstruction of the 1918 influenza pandemic virus. Dec 2019 [internet publication].Полный текст

11. Stephenson I, Zambon M. The epidemiology of influenza. Occup Med (Lond). 2002 Aug;52(5):241-7. Аннотация

12. Klimov A, Rocha E, Hayden FG, et al. Prolonged shedding of amantadine-resistant influenza A viruses by immunodeficient patients: detection by polymerase chain reaction-restriction analysis. J Infect Dis. 1995 Nov;172(5):1352-5. Аннотация

13. Centers for Disease Control and Prevention (CDC). Estimates of deaths associated with seasonal influenza - United States, 1976-2007. MMWR Morb Mortal Wkly Rep. 2010 Aug 27;59(33):1057-62.Полный текст  Аннотация

14. Kostova D, Reed C, Finelli L, et al. Influenza illness and hospitalizations averted by influenza vaccination in the United States, 2005-2011. PLoS One. 2013 Jun 19;8(6):e6631.Полный текст  Аннотация

15. Centers for Disease Control and Prevention. Influenza (flu). Oct 2021 [internet publication].Полный текст

16. Committee on Infectious Diseases. Recommendations for prevention and control of influenza in children, 2021-2022. Pediatrics. 2021 Oct;148(4):.Полный текст  Аннотация

17. Hutchinson AF, Ghimire AK, Thompson MA, et al. A community-based, time-matched, case-control study of respiratory viruses and exacerbations of COPD. Respir Med. 2007 Dec;101(12):2472-81. Аннотация

18. Kopsaftis Z, Wood-Baker R, Poole P. Influenza vaccine for chronic obstructive pulmonary disease (COPD). Cochrane Database Syst Rev. 2018 Jun 26;(6):CD002733.Полный текст  Аннотация

19. Bekkat-Berkani R, Wilkinson T, Buchy P, et al. Seasonal influenza vaccination in patients with COPD: a systematic literature review. BMC Pulm Med. 2017 May 3;17(1):79.Полный текст  Аннотация

20. Nichol KL, Nordin J, Mullooly J, et al. Influenza vaccination and reduction in hospitalizations for cardiac disease and stroke among the elderly. N Engl J Med. 2003 Apr 3;348(14):1322-32.Полный текст  Аннотация

21. Dos Santos G, Tahrat H, Bekkat-Berkani R. Immunogenicity, safety, and effectiveness of seasonal influenza vaccination in patients with diabetes mellitus: asystematic review. Hum Vaccin Immunother. 2018;14(8):1853-66.Полный текст  Аннотация

22. Orzeck EA, Shi N, Blumentals WA. Oseltamivir and the risk of influenza-related complications and hospitalizations in patients with diabetes. Clin Ther. 2007 Oct;29(10):2246-55. Аннотация

23. Mehta SR, Afenyi-Annan A, Byrns PJ, et al. Opportunities to improve outcomes in sickle cell disease. Am Fam Physician. 2006 Jul 15;74(2):303-10. Аннотация

24. Kim YJ, Boeckh M, Englund JA. Community respiratory virus infections in immunocompromised patients: hematopoietic stem cell and solid organ transplant recipients, and individuals with human immunodeficiency virus infection. Semin Respir Crit Care Med. 2007 Apr;28(2):222-42. Аннотация

25. Zhang W, Sun H, Atiquzzaman M, et al. Influenza vaccination for HIV-positive people: systematic review and network meta-analysis. Vaccine. 2018 Jun 27;36(28):4077-86. Аннотация

26. Danziger-Isakov L, Kumar D, AST ID Community of Practice. Vaccination of solid organ transplant candidates and recipients: guidelines from the American Society of Transplantation Infectious Diseases Community of Practice. Clin Transplant. 2019 Sep;33(9):e13563. Аннотация

27. Beck CR, McKenzie BC, Hashim AB, et al. Influenza vaccination for immunocompromised patients: systematic review and meta-analysis from a public health policy perspective. PLoS One. 2011 Dec 22;6(12):e29249.Полный текст  Аннотация

28. McKittrick N, Frank I, Jacobson JM, et al. Improved immunogenicity with high-dose seasonal influenza vaccine in HIV-infected persons: a single-center, parallel, randomized trial. Ann Intern Med. 2013 Jan 1;158(1):19-26. Аннотация

29. Madhi SA, Cutland CL, Kuwanda L, et al.; Maternal Flu Trial (Matflu) Team. Influenza vaccination of pregnant women and protection of their infants. N Engl J Med. 2005 Oct 21;54(41):1050-2.Полный текст  Аннотация

30. Kumar D, Campbell P, Hoschler K, et al. Randomized controlled trial of adjuvanted versus nonadjuvanted influenza vaccine in kidney transplant recipients. Transplantation. 2016 Mar;100(3):662-9. Аннотация

31. Grohskopf LA, Alyanak E, Ferdinands JM, et al. Prevention and control of seasonal influenza with vaccines: recommendations of the advisory committee on immunization practices, United States, 2021-22 influenza season. MMWR Recomm Rep. 2021 Aug 27;70(5):1-28.Полный текст  Аннотация

32. Hak E, Nordin J, Wei F, et al. Influence of high-risk medical conditions on the effectiveness of influenza vaccination among elderly members of 3 large managed-care organizations. Clin Infect Dis. 2002 Aug 15;35(4):370-7. Аннотация

33. Centers for Disease Control and Prevention. Recommendations for obstetric health care providers related to use of antiviral medications in the treatment and prevention of influenza. Nov 2020 [internet publication].Полный текст

34. American College of Obstetricians and Gynecologists. Assessment and treatment of pregnant women with suspected or confirmed influenza: ACOG Committee Opinion No. 753. Obstet Gynecol. 2018 Oct;132(4):e169-73.Полный текст  Аннотация

35. Nunes MC, Aqil AR, Omer SB, Madhi SA. The effects of influenza vaccination during pregnancy on birth outcomes: a systematic review and meta-analysis. Am J Perinatol. 2016 Sep;33(11):1104-14.Полный текст  Аннотация

36. American College of Obstetricians and Gynecologists. Influenza vaccination during pregnancy: ACOG Committee Opinion No. 732. Obstet Gynecol. 2018 Apr;131(4):e109-14.Полный текст  Аннотация

37. Polyzos KA, Konstantelias AA, Pitsa CE, et al. Maternal influenza vaccination and risk for congenital malformations: a systematic review and meta-analysis. Obstet Gynecol. 2015 Nov;126(5):1075-84. Аннотация

38. Advisory Committee on Immunization Practices; Centers for Disease Control and Prevention (CDC). Immunization of health-care personnel: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep. 2011 Nov 25;60(RR-7):1-45.Полный текст  Аннотация

39. Bernstein HH, Starke JR; American Academy of Pediatrics; et al. Policy statement - recommendation for mandatory influenza immunization of all health care personnel. Pediatrics. 2010 Oct;126(4):809-15. Аннотация

40. Centers for Disease Control and Prevention. Frequently asked influenza (flu) questions: 2021-2022 season. Oct 2021 (internet publication].Полный текст

41. Jackson LA, Gaglani MJ, Keyserling HL, et al. Safety, efficacy, and immunogenicity of an inactivated influenza vaccine in healthy adults: a randomized, placebo-controlled trial over two influenza seasons. BMC Infect Dis. 2010 Mar 17;10:71. Аннотация

42. Beyer WE, Nauta JJ, Palache AM, et al. Immunogenicity and safety of inactivated influenza vaccines in primed populations: a systematic literature review and meta-analysis. Vaccine. 2011 Aug 5;29(34):5785-92. Аннотация

43. Demicheli V, Jefferson T, Ferroni E, et al. Vaccines for preventing influenza in healthy adults. Cochrane Database Syst Rev. 2018 Feb 1;(2):CD001269.Полный текст  Аннотация

44. Bitterman R, Eliakim-Raz N, Vinograd I, et al. Influenza vaccines in immunosuppressed adults with cancer. Cochrane Database Syst Rev. 2018 Feb 1;(2):CD008983.Полный текст  Аннотация

45. Jefferson T, Rivetti A, Di Pietrantonj C, et al. Vaccines for preventing influenza in healthy children. Cochrane Database Syst Rev. 2018 Feb 1;(2):CD004879.Полный текст  Аннотация

46. Demicheli V, Jefferson T, Di Pietrantonj C, et al. Vaccines for preventing influenza in the elderly. Cochrane Database Syst Rev. 2018 Feb 1;(2):CD004876.Полный текст  Аннотация

47. Rondy M, El Omeiri N, Thompson MG, et al. Effectiveness of influenza vaccines in preventing severe influenza illness among adults: a systematic review and meta-analysis of test-negative design case-control studies. J Infect. 2017 Nov;75(5):381-94.Полный текст  Аннотация

48. Vasileiou E, Sheikh A, Butler C, et al. Effectiveness of influenza vaccines in asthma: a systematic review and meta-analysis. Clin Infect Dis. 2017 Oct 15;65(8):1388-95.Полный текст  Аннотация

49. Public Health England. National flu immunisation programme plan. Dec 2020 [internet publication].Полный текст

50. Englund JA, Walter E, Black S, et al. Safety and immunogenicity of trivalent inactivated influenza vaccine in infants: a randomized double-blind placebo-controlled study. Pediatr Infect Dis J. 2010 Feb;29(2):105-10. Аннотация

51. Sukumaran L, McCarthy NL, Kharbanda EO, et al. Infant hospitalizations and mortality after maternal vaccination. Pediatrics. 2018 Mar;141(3):e20173310.Полный текст  Аннотация

52. Thompson MG, Kwong JC, Regan AK, et al; PREVENT Workgroup. Influenza vaccine effectiveness in preventing influenza-associated hospitalizations during pregnancy: a multi-country retrospective test negative design study, 2010-2016. Clin Infect Dis. 2019 Apr 24;68(9):1444-53.Полный текст  Аннотация

53. Nunes MC, Madhi SA. Influenza vaccination during pregnancy for prevention of influenza confirmed illness in the infants: a systematic review and meta-analysis. Hum Vaccin Immunother. 2017 Mar 4;14(3):758-66.Полный текст  Аннотация

54. Greenhawt M, Turner PJ, Kelso JM. Administration of influenza vaccines to egg allergic recipients: a practice parameter update 2017. Ann Allergy Asthma Immunol. 2018 Jan;120(1):49-52.Полный текст  Аннотация

55. Centers for Disease Control and Prevention, Advisory Committee on Immunization Practices. Recommended child and adolescent immunization schedule for ages 18 years or younger, United States, 2021. Feb 2021 [internet publication].Полный текст

56. Centers for Disease Control and Prevention, Advisory Committee on Immunization Practices. Recommended adult immunization schedule for ages 19 years or older, United States, 2021. Feb 2021 [internet publication].Полный текст

57. Fukuda K, Kieny MP. Different approaches to influenza vaccination. N Engl J Med. 2006 Dec 14;355(24):2586-7.Полный текст  Аннотация

58. Wilde JA, McMillan JA, Serwint J, et al. Effectiveness of influenza vaccine in health care professionals: a randomized trial. JAMA. 1999 Mar 10;281(10):908-13.Полный текст  Аннотация

59. Bridges CB, Thompson WW, Meltzer MI, et al. Effectiveness and cost-benefit of influenza vaccination of healthy working adults: a randomized controlled trial. JAMA. 2000 Oct 4;284(13):1655-63.Полный текст  Аннотация

60. Edwards KM, Dupont WD, Westrich MK, et al. A randomized controlled trial of cold-adapted and inactivated vaccines for the prevention of influenza A disease. J Infect Dis. 1994 Jan;169(1):68-76. Аннотация

61. Ohmit SE, Victor JC, Rotthoff JR, et al. Prevention of antigenically drifted influenza by inactivated and live attenuated vaccines. N Engl J Med. 2006 Dec 14;355(24):2513-22.Полный текст  Аннотация

62. DiazGranados CA, Denis M, Plotkin S. Seasonal influenza vaccine efficacy and its determinants in children and non-elderly adults: a systematic review with meta-analyses of controlled trials. Vaccine. 2012 Dec 17;31(1):49-57. Аннотация

63. Manzoli L, Ioannidis JP, Flacco ME, et al. Effectiveness and harms of seasonal and pandemic influenza vaccines in children, adults and elderly: a critical review and re-analysis of 15 meta-analyses. Hum Vaccin Immunother. 2012 Jul;8(7):851-62.Полный текст  Аннотация

64. Osterholm MT, Kelley NS, Sommer A, et al. Efficacy and effectiveness of influenza vaccines: a systematic review and meta-analysis. Lancet Infect Dis. 2012 Jan;12(1):36-44. Аннотация

65. Monto AS, Rotthoff J, Teich E, et al. Detection and control of outbreaks in well-vaccinated nursing home populations. Clin Infect Dis. 2004 Aug 15;39(4):459-64. Аннотация

66. Nichol KL, Nordin JD, Nelson DB, et al. Effectiveness of influenza vaccine in the community-dwelling elderly. N Engl J Med. 2007 Oct 4;357(14):1373-81.Полный текст  Аннотация

67. De Villiers PJ, Steele AD, Hiemstra LA, et al. Efficacy and safety of a live attenuated influenza vaccine in adults 60 years of age and older. Vaccine. 2009 Dec 10;28(1):228-34. Аннотация

68. Jefferson T, Rivetti D, Rivetti A, et al. Efficacy and effectiveness of influenza vaccines in elderly people: a systematic review. Lancet. 2005 Oct 1;366(9492):1165-74. Аннотация

69. Armstrong BG, Mangtani P, Fletcher A, et al. Effect of influenza vaccination on excess deaths occurring during periods of high circulation of influenza: cohort study in elderly people. BMJ. 2004 Sep 18;329(7467):660.Полный текст  Аннотация

70. Cools HJ, Gussekloo J, Remmerswaal JE, et al. Benefits of increasing the dose of influenza vaccine in residents of long-term care facilities: a randomized placebo-controlled trial. J Med Virol. 2009 May;81(5):908-14. Аннотация

71. DiazGranados CA, Dunning AJ, Kimmel M, et al. Efficacy of high-dose versus standard-dose influenza vaccine in older adults. N Engl J Med. 2014 Aug 14;371(7):635-45.Полный текст  Аннотация

72. Nace DA, Lin CJ, Ross TM, et al. Randomized, controlled trial of high-dose influenza vaccine among frail residents of long-term care facilities. J Infect Dis. 2015 Jun 15;211(12):1915-24.Полный текст  Аннотация

73. Lee JKH, Lam GKL, Shin T, et al. Efficacy and effectiveness of high-dose versus standard-dose influenza vaccination for older adults: a systematic review and meta-analysis. Expert Rev Vaccines. 2018 May 16;17(5):435-43. Аннотация

74. Samson SI, Leventhal PS, Salamand C, et al. Immunogenicity of high-dose trivalent inactivated influenza vaccine: a systematic review and meta-analysis. Expert Rev Vaccines. 2019 Feb 13;18(3):295-308. Аннотация

75. Lehmann HC, Hartung HP, Kieseier BC, et al. Guillain-Barré syndrome after exposure to influenza virus. Lancet Infect Dis. 2010 Sep;10(9):643-51. Аннотация

76. Lasky T, Terracciano GJ, Magder L, et al. The Guillain-Barré syndrome and the 1992-1993 and 1993-1994 influenza vaccines. N Engl J Med. 1998 Dec 17;339(25):1797-802. Аннотация

77. Centers for Disease Control and Prevention. Influenza signs and symptoms and the role of laboratory diagnostics. Aug 2020 [internet publication].Полный текст

78. Call SA, Vollenweider MA, Hornung CA, et al. Does this patient have influenza? JAMA. 2005 Feb 23;293(8):987-97. Аннотация

79. Hayden FG, Fritz R, Lobo MC, et al. Local and systemic cytokine responses during experimental human influenza A virus infection. Relation to symptom formation and host defense. J Clin Invest. 1998 Feb 1;101(3):643-9.Полный текст  Аннотация

80. Monto AS, Gravenstein S, Elliott M, et al. Clinical signs and symptoms predicting influenza infection. Arch Intern Med. 2000 Nov 27;160(21):3243-7.Полный текст  Аннотация

81. Nicholson KG, Kent J, Hammersley V, et al. Acute viral infections of upper respiratory tract in elderly people living in the community: comparative, prospective, population based study of disease burden. BMJ. 1997 Oct 25;315(7115):1060-4.Полный текст  Аннотация

82. Vesikari T, Beran J, Durviaux S, et al. Use of real-time polymerase chain reaction (rtPCR) as a diagnostic tool for influenza infection in a vaccine efficacy trial. J Clin Virol. 2012 Jan;53(1):22-8. Аннотация

83. Egilmezer E, Walker GJ, Bakthavathsalam P, et al. Systematic review of the impact of point-of-care testing for influenza on the outcomes of patients with acute respiratory tract infection. Rev Med Virol. 2018 Sep;28(5):e1995. Аннотация

84. Huang HS, Tsai CL, Chang J, et al. Multiplex PCR system for the rapid diagnosis of respiratory virus infection: systematic review and meta-analysis. Clin Microbiol Infect. 2017 Oct;24(10):1055-63.Полный текст  Аннотация

85. Glezen WP, Taber LH, Frank AL, et al. Influenza virus infections in infants. Pediatr Infect Dis J. 1997 Nov;16(11):1065-8. Аннотация

86. Peltola V, Ziegler T, Ruuskanen O. Influenza A and B virus infections in children. Clin Infect Dis. 2003 Feb 1;36(3):299-305. Аннотация

87. Glezen WP. Influenza viruses. In: Feigin RD, Cherry JD, Demmler GJ, et al., eds. Textbook of pediatric infectious diseases. 5th ed. Philadelphia, PA: WB Saunders; 2004:2252-69.

88. Govaert TM, Dinant GJ, Aretz K, et al. The predictive value of influenza symptomatology in elderly people. Fam Pract. 1998 Feb;15(1):16-22.Полный текст  Аннотация

89. Walsh EE, Cox C, Falsey AR. Clinical features of influenza A virus infection in older hospitalized persons. J Am Geriatr Soc. 2002 Sep;50(9):1498-503. Аннотация

90. Neuzil KM, O'Connor TZ, Gorse GJ, et al. Recognizing influenza in older patients with chronic obstructive pulmonary disease who have received influenza vaccine. Clin Infect Dis. 2003 Jan 15;36(2):169-74.Полный текст  Аннотация

91. Ohmit SE, Monto AS. Symptomatic predictors of influenza virus positivity in children during the influenza season. Clin Infect Dis. 2006 Sep 1;43(5):564-8.Полный текст  Аннотация

92. Simonsen L. The global impact of influenza on morbidity and mortality. Vaccine. 1999;17(suppl 1):S3-10. Аннотация

93. Lang S, Kansy B. Cervical lymph node diseases in children. GMS Curr Top Otorhinolaryngol Head Neck Surg. 2014;13:Doc08.Полный текст  Аннотация

94. Miller JM, Binnicker MJ, Campbell S, et al. A guide to utilization of the microbiology laboratory for diagnosis of infectious diseases: 2018 update by the Infectious Diseases Society of America and the American Society for Microbiology. Clin Infect Dis. 2018 Aug 31;67(6):e1-94.Полный текст  Аннотация

95. Merckx J, Wali R, Schiller I, et al. Diagnostic accuracy of novel and traditional rapid tests for influenza infection compared with reverse transcriptase polymerase chain reaction: a systematic review and meta-analysis. Ann Intern Med. 2017 Sep 19;167(6):394-409. Аннотация

96. Bruning AHL, Leeflang MMG, Vos JMBW, et al. Rapid tests for influenza, respiratory syncytial virus, and other respiratory viruses: a systematic review and meta-analysis. Clin Infect Dis. 2017 Sep 15;65(6):1026-32.Полный текст  Аннотация

97. Petrozzino JJ, Smith C, Atkinson MJ. Rapid diagnostic testing for seasonal influenza: an evidence-based review and comparison with unaided clinical diagnosis. J Emerg Med. 2010 Oct;39(4):476-90. Аннотация

98. Marrie TJ. Community-acquired pneumonia. Clin Infect Dis. 1994 Apr;18(4):501-13. Аннотация

99. Solomon DA, Sherman AC, Kanjilal S. Influenza in the COVID-19 era. JAMA. 2020 Oct 6;324(13):1342-3.Полный текст  Аннотация

100. Shay DK, Holman RC, Newman RD, et al. Bronchiolitis-associated hospitalizations among US children, 1980-1996. JAMA. 1999 Oct 20;282(15):1440-6.Полный текст  Аннотация

101. Wald TG, Miller BA, Shult P, et al. Can respiratory syncytial virus and influenza A be distinguished clinically in institutionalized older persons? J Am Geriatr Soc. 1995 Feb;43(2):170-4. Аннотация

102. Rose EB, Wheatley A, Langley G, et al. Respiratory syncytial virus seasonality - United States, 2014-2017. MMWR Morb Mortal Wkly Rep. 2018 Jan 19;67(2):71-6.Полный текст  Аннотация

103. Hall CB. Respiratory syncytial virus and parainfluenza virus. N Engl J Med. 2001 Jun 21;344(25):1917-28. Аннотация

104. Wendt CH, Hertz MI. Respiratory syncytial virus and parainfluenza virus infections in the immunocompromised host. Semin Respir Infect. 1995 Dec;10(4):224-31. Аннотация

105. Denny FW, Clyde WA Jr. Acute lower respiratory tract infections in nonhospitalized children. J Pediatr. 1986 May;108(5 Pt 1):635-46. Аннотация

106. Frank AL, Couch RB, Griffis CA, et al. Comparison of different tissue cultures for isolation and quantitation of influenza and parainfluenza viruses. J Clin Microbiol. 1979 Jul;10(1):32-6. Аннотация

107. Ray CG, Minnich LL. Efficiency of immunofluorescence for rapid detection of common respiratory viruses. J Clin Microbiol. 1987 Feb;25(2):355-7. Аннотация

108. Osiowy C. Direct detection of respiratory syncytial virus, parainfluenza virus, and adenovirus in clinical respiratory specimens by a multiplex reverse transcription-PCR assay. J Clin Microbiol. 1998 Nov;36(11):3149-54. Аннотация

109. Fiore AE, Fry A, Shay D, et al. Antiviral agents for the treatment and chemoprophylaxis of influenza: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep. 2011 Jan 21;60(1):1-24.Полный текст  Аннотация

110. National Institute for Health and Care Excellence. Oseltamivir, amantadine (review) and zanamivir for the prophylaxis of influenza. Sep 2008 [internet publication].Полный текст

111. Cox NJ, Fukuda K. Influenza. Infect Dis Clin North Am. 1998 Mar;12(1):27-38. Аннотация

112. Centers for Disease Control and Prevention. Influenza antiviral medications: summary for clinicians. Sept 2021 [internet publication].Полный текст

113. Public Health England. Influenza: treatment and prophylaxis using anti-viral agents. Oct 2019 [internet publication].Полный текст

114. Jefferson T, Jones M, Doshi P, et al. Neuraminidase inhibitors for preventing and treating influenza in healthy adults: systematic review and meta-analysis. BMJ. 2009 Dec 8;339:b5106.Полный текст  Аннотация

115. Shun-Shin M, Thompson M, Heneghan C, et al. Neuraminidase inhibitors for treatment and prophylaxis of influenza in children: systematic review and meta-analysis of randomised controlled trials. BMJ. 2009 Aug 10;339:b3172.Полный текст  Аннотация

116. Doll MK, Winters N, Boikos C, et al. Safety and effectiveness of neuraminidase inhibitors for influenza treatment, prophylaxis, and outbreak control: a systematic review of systematic reviews and/or meta-analyses. J Antimicrob Chemother. 2017 Nov 1;72(11):2990-3007. Аннотация

117. Venkatesan S, Myles PR, Leonardi-Bee J, et al. Impact of outpatient neuraminidase inhibitor treatment in patients infected with influenza A(H1N1)pdm09 at high risk of hospitalization: an individual participant data metaanalysis. Clin Infect Dis. 2017 May 15;64(10):1328-34. Аннотация

118. Jackson RJ, Cooper KL, Tappenden P, et al. Oseltamivir, zanamivir and amantadine in the prevention of influenza: a systematic review. J Infect. 2011 Jan;62(1):14-25. Аннотация

119. Jefferson T, Jones MA, Doshi P, et al. Neuraminidase inhibitors for preventing and treating influenza in healthy adults and children. Cochrane Database Syst Rev. 2014;(4):CD008965.Полный текст  Аннотация

120. Heneghan CJ, Onakpoya I, Thompson M, et al. Zanamivir for influenza in adults and children: systematic review of clinical study reports and summary of regulatory comments. BMJ. 2014 Apr 9;348:g2547.Полный текст  Аннотация

121. Jefferson T, Jones M, Doshi P, et al. Oseltamivir for influenza in adults and children: systematic review of clinical study reports and summary of regulatory comments. BMJ. 2014 Apr 9;348:g2545.Полный текст  Аннотация

122. Cohen D. Complications: tracking down the data on oseltamivir. BMJ. 2009 Dec 8;339:b5387. Аннотация

123. Doshi P. Neuraminidase inhibitors - the story behind the Cochrane review. BMJ. 2009 Dec 8;339:b5164. Аннотация

124. Jefferson T, Doshi P, Thompson M, et al. Ensuring safe and effective drugs: who can do what it takes? BMJ. 2011 Jan 11;342:c7258. Аннотация

125. Dobson J, Whitley RJ, Pocock S, et al. Oseltamivir treatment for influenza in adults: a meta-analysis of randomised controlled trials. Lancet. 2015 May 2;385(9979):1729-37. Аннотация

126. Uyeki T. Antiviral treatment for patients hospitalized with 2009 pandemic influenza A (H1N1). N Engl J Med. 2009 Dec 3;361(23):e110. Аннотация

127. Wang K, Shun-Shin M, Gill P, et al. Neuraminidase inhibitors for preventing and treating influenza in children (published trials only). Cochrane Database Syst Rev. 2012 Apr 18;(1):CD002744.Полный текст  Аннотация

128. Stiver G. The treatment of influenza with antiviral drugs. CMAJ. 2003 Jan 7;168(1):49-56.Полный текст  Аннотация

129. Heinonen S, Silvennoinen H, Lehtinen P, et al. Early oseltamivir treatment of influenza in children 1-3 years of age: a randomized controlled trial. Clin Infect Dis. 2010 Oct 15;51(8):887-94. Аннотация

130. Ikematsu H, Hayden FG, Kawaguchi K, et al. Baloxavir marboxil for prophylaxis against influenza in household contacts. N Engl J Med. 2020 Jul 23;383(4):309-20.Полный текст  Аннотация

131. US Food and Drug Administration. FDA Drug Safety Communication: FDA updates warnings for oral and injectable fluoroquinolone antibiotics due to disabling side effects. Jul 2016 [internet publication].Полный текст

132. European Medicines Agency. Quinolone- and fluoroquinolone-containing medicinal products. Mar 2019 [internet publication].Полный текст

133. US Food and Drug Administration. FDA reinforces safety information about serious low blood sugar levels and mental health side effects with fluoroquinolone antibiotics; requires label changes. Jul 2018 [internet publication].Полный текст

134. US Food and Drug Administration. FDA warns about increased risk of ruptures or tears in the aorta blood vessel with fluoroquinolone antibiotics in certain patients. Dec 2018 [internet publication].Полный текст

135. Dowell SF, Butler JC, Giebink GS, et al. Acute otitis media: management and surveillance in an era of pneumococcal resistance - a report from the Drug-resistant Streptococcus Pneumoniae Therapeutic Working Group. Pediatr Infect Dis J. 1999 Jan;18(1):1-9. Аннотация

136. Lieberthal AS, Carroll AE, Chonmaitree T, et al. The diagnosis and management of acute otitis media. Pediatrics. 2013 Feb 25;131(3):e964-99.Полный текст  Аннотация

137. McAllister L, Anderson J, Werth K, et al. Needle-free jet injection for administration of influenza vaccine: a randomised non-inferiority trial. Lancet. 2014 Aug 23;384(9944):674-81. Аннотация

138. Moscona A. Medical management of influenza infection. Annu Rev Med. 2008 Feb;59:397-413. Аннотация

139. Ilyushina NA, Hoffmann E, Salomon R, et al. Amantadine-oseltamivir combination therapy for H5N1 influenza virus infection in mice. Antivir Ther. 2007;12(3):363-70. Аннотация

140. Smee DF, Hurst BL, Wong MH, et al. Effects of the combination of favipiravir (T-705) and oseltamivir on influenza A virus infections in mice. Antimicrob Agents Chemother. 2010 Jan;54(1):126-33.Полный текст  Аннотация

141. Ilyushina NA, Bovin NV, Webster RG, et al. Combination chemotherapy, a potential strategy for reducing the emergence of drug-resistant influenza A variants. Antiviral Res. 2006 Jul;70(3):121-31. Аннотация

142. Duval X, van der Werf S, Blanchon T, et al. Efficacy of oseltamivir-zanamivir combination compared to each monotherapy for seasonal influenza: a randomized placebo-controlled trial. PLoS Med. 2010 Nov 2;7(11):e1000362.Полный текст  Аннотация

143. Belser JA, Lu X, Szretter KJ, et al. DAS181, a novel sialidase fusion protein, protects mice from lethal avian influenza H5N1 virus infection. J Infect Dis. 2007 Oct 31;196(10):1493-9.Полный текст  Аннотация

144. Moscona A, Porotto M, Palmer S, et al. A recombinant sialidase fusion protein effectively inhibits human parainfluenza viral infection in vitro and in vivo. J Infect Dis. 2010 Jul 15;202(2):234-41.Полный текст  Аннотация

145. Wu C, Chen W, Chen J, H. Preparation of monoPEGylated Cyanovirin-N's derivative and its anti-influenza A virus bioactivity in vitro and in vivo. J Biochem. 2015 Jun;157(6):539-48. Аннотация

146. Švančarová P, Svetlíková D, Betáková T. Induction of interferon lambda in influenza A virus infected cells treated with shRNAs against M1 transcript. Acta Virol. 2015 Jun;59(2):148-55. Аннотация

147. Furuta Y, Gowen BB, Takahashi K, et al. Favipiravir (T-705), a novel viral RNA polymerase inhibitor. Antiviral Res. 2013 Nov;100(2):446-54.Полный текст  Аннотация

148. Beigel J, Bray M. Current and future antiviral therapy of severe seasonal and avian influenza. Antiviral Res. 2008 Apr;78(1):91-102.Полный текст  Аннотация

149. Jones S, Evans K, McElwaine-Johnn H, et al. DNA vaccination protects against an influenza challenge in a double-blind randomised placebo-controlled phase 1b clinical trial. Vaccine. 2009 Apr 21;27(18):2506-12. Аннотация

150. Smith LR, Wloch MK, Ye M, et al. Phase 1 clinical trials of the safety and immunogenicity of adjuvanted plasmid DNA vaccines encoding influenza A virus H5 hemagglutinin. Vaccine. 2010 Mar 16;28(13):2565-72. Аннотация

151. GBD 2017 Influenza Collaborators. Mortality, morbidity, and hospitalisations due to influenza lower respiratory tract infections, 2017: an analysis for the Global Burden of Disease Study 2017. Lancet Respir Med. 2018 Dec 12;7(1):69-89.Полный текст  Аннотация

152. Schwarzmann SW, Adler JL, Sullivan RJ Jr, et al. Bacterial pneumonia during the Hong Kong influenza epidemic of 1968-1969. Arch Intern Med. 1971 Jun;127(6):1037-41. Аннотация

153. Newland JG, Laurich VM, Rosenquist AW, et al. Neurologic complications in children hospitalized with influenza: characteristics, incidence, and risk factors. J Pediatr. 2007 Mar;150(3):306-10. Аннотация

154. Winther B, Block SL, Reisinger K, et al. Impact of oseltamivir treatment on the incidence and course of acute otitis media in children with influenza. Int J Pediatr Otorhinolaryngol. 2010 Jun;74(6):684-8. Аннотация

155. Casey JR, Pichichero ME. Changes in frequency and pathogens causing acute otitis media in 1995-2003. Pediatr Infect Dis J. 2004 Sep;23(9):824-8. Аннотация

156. Gamboa ET, Eastwood AB, Hays AP, et al. Isolation of influenza virus from muscle in myoglobinuric polymyositis. Neurology. 1979 Oct;29(10):1323-35. Аннотация

157. Dell KM, Schulman SL. Rhabdomyolysis and acute renal failure in a child with influenza A infection. Pediatr Nephrol. 1997 Jun;11(3):363-5. Аннотация

158. Dietzman DE, Schaller JG, Ray CG, et al. Acute myositis associated with influenza B infection. Pediatrics. 1976 Feb;57(2):255-8. Аннотация

159. Brinar VV, Habek M, Brinar M, et al. The differential diagnosis of acute transverse myelitis. Clin Neurol Neurosurg. 2006 Mar;108(3):278-83. Аннотация

160. Ropper AH. The Guillain-Barré syndrome. N Engl J Med. 1992 Apr 23;326(17):1130-6. Аннотация

161. MacDonald K, Osterholm M, Hedberg C, et al. Toxic shock syndrome: a newly recognized complication of influenza and influenza-like illness. JAMA. 1987 Feb 27;257(8):1053-8. Аннотация

162. US Food and Drug Administration. FDA warns of fraudulent and unapproved flu products. Mar 2018 [internet publication].Полный текст

Использование этого контента попадает под действие нашего заявления об отказе от ответственности